Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Disease area: Airway diseases

Abstract

Objectives: To investigate the efficacy of the inhaled supplementary short-acting beta2-agonists (SABA) administered before the performance of daily activity (the SABA Assust Use) in patients with COPD. Methods: Thirty outpatients with moderate to severe COPD (Stage II - IV), regular use of tiotropium bromide alone, and dyspnea during daily activities, were enrolled. Subjects self-administered 20μg of inhaled procaterol hydrochloride before daily activities no more than four times daily. Dyspnea symptom scores, St George‘s Respiratory Questionnaire (SGRQ) activity domains, impulse oscillometry system parameters, and pulmonary function tests were recorded at the beginning and end of the 2-week study. Results: More than 80% of subjects reported dyspnea when performing the following activities: walking up a slope (100.0%), climbing stairs (100.0%), gardening (93.3%), walking on flat ground (90.0%), bathing (86.7%), getting on a bus or train (83.3%), and changing clothes (80.0%). After 2 weeks, subjects with Stage III significantly improved dyspnea scores (walking up a slope (p=0.047), climbing stairs (p=0.014), gardening (p=0.034), walking on flat ground (p=0.006), getting on a bus or train (p=0.039), and changing clothes (p=0.045)). Both symptoms and activity SGRQ domains significantly improved in subjects with Stage III (p=0.036 and p=0.028, respectively). Resistance of small airways (R5-R20) and low-frequency reactance area (AX) significantly improved in subjects with Stage III (p=0.003 and p=0.004, respectively). No significant changes were found in pulmonary function tests. Conclusion: The SABA Assist Use improved dyspnea symptoms in subjects with Stage III COPD.

Rating:

Share or cite this content

Citations should be made in the following way:
H. Ohbayashi, M. Adachi (Mizunami, Tokyo, Japan). Pretreatment with inhaled procaterol improves symptoms of dyspnea and quality of life in patients with severe COPD. Eur Respir J 2012; 40: Suppl. 56, 2111

Member's Comments

No comment yet.

Related content which might interest you: Effects of adding salmeterol to inhaled corticosteroids on lung function and quality of life in patients with mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Formoterol Turbuhaler® reduces the need for relief medication in children with mild to moderate asthma and improves quality of life Source: Eur Respir J 2001; 18: Suppl. 33, 291s Year: 2001 Intranasal budesonide improves quality of life in patient with COPD and chronic nasal symptoms Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Source: Eur Respir J 2002; 19: 209-216 Year: 2002 Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002 Sertraline effects on dyspnea in patients with severe COPD Source: Eur Respir J 2005; 26: Suppl. 49, 288s Year: 2005 Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Once-daily QVA149 improves symptom scores in patients with COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Relationship between severity of bronchial and systemic inflammation, and dyspnea, exercise performance and quality of life in patients with stable COPD Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006 Quality of life of patients with asthma exacerbations treated with high doses of inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 114s Year: 2002 ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD Source: Eur Respir J 2001; 17: 1132-1137 Year: 2001 Ensifentrine added on to tiotropium significantly improves lung function, symptoms and QoL in symptomatic COPD patients regardless of baseline reversibility Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 The impact of frequent exacerbations on air-trapping, dyspnea, exercise capacity and quality of life in stable COPD Source: Eur Respir J 2006; 28: Suppl. 50, 176s Year: 2006 Poor quality of life is associated with frequent exacerbations in moderate-to-severe COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 190s Year: 2001 Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013